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Abstract The adipocyte-derived hormone leptin signals the sta-
tus of body energy stores by activating its receptor in hypotha-
lamic nuclei. In contrast to the initial expectations, leptin treat-
ment of human obesity was largely unsuccessful. One
explanation for this is the marked leptin resistance, which likely
operates in part at the receptor level. The leptin receptor is a
member of the class I cytokine receptor family, which uses the
Janus kinase/signal transducer and activator of transcription
pathway as a major signaling route. In this review, we focus
on the molecular mechanisms underlying leptin receptor activa-
tion. Di¡erent modes of leptin-induced clustering of the ectodo-
mains and the subsequent signaling events will be discussed.
% 2003 Federation of European Biochemical Societies. Pub-
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1. Introduction
Leptin and its receptor are essential components in the
complex genetic wiring diagram underlying energy homeosta-
sis and body weight. Spontaneous mutations in leptin or in its
receptor result in marked obesity in both mice [1,2] and man
[3,4]. Leptin is mainly produced in white adipose tissue [2]
although expression has also been demonstrated in the fundus
of the stomach [5] and in skeletal muscle [6]. The long, signal-
ing-competent isoform of the leptin receptor (LR) shows high
expression peaks in the feeding centers of the hypothalamus
[7], consistent with leptin being the a¡erent signal informing
the central nervous system of the body fat status. This concept
is further supported by the observation that leptin-de¢cient
(ob3=3) mice and men can be successfully treated with leptin
[8,9]. Leptin was therefore initially considered a miracle drug
for treatment of obesity. However, obese people often have
elevated leptin levels [10] and leptin administration showed
only very limited e¡ects [11]. Recent data have indicated
that this is likely due to desensitization for the leptin signal,
a phenomenon now often referred to as leptin resistance. This
may be situated at least at two distinct levels : saturable trans-
port of leptin across the blood^brain barrier, and abnormal-
ities at the level of LR activation and/or signal transduction
[12]. Besides its role via the central nervous system, leptin also
has direct e¡ects on a series of peripheral tissues, implying a
much more complex leptin axis than was originally antici-
pated [13].
To date, six splice variants of the LR have been identi¢ed.
The long isoform or Ob-Rb (further referred to as LRlo)
consists of 1162 amino acids and is the only LR isoform
with clearly demonstrated signaling capability. It is highly ex-
pressed in hypothalamic centers although expression at func-
tional levels has also been demonstrated in a number of other
tissues including liver, lung, testis, etc. Neuronal-speci¢c abla-
tion of Ob-Rb results in obesity, clearly indicating that the
weight-reducing properties of leptin are exerted centrally [14].
Four short isoforms (Ob-Ra, Ob-Rc, Ob-Rd, and Ob-Rf; Ob-
Ra will be further referred to as LRsh) with shortened intra-
cellular tails have been identi¢ed. High expression levels of
Ob-Ra and Ob-Rc can be found in choroid plexus and brain
microvessels [7], suggesting their role in blood^brain barrier
transport. This idea is further supported by observations in
mouse models for obesity [15] and by the use of an in vitro
leptin transport assay [16]. A secreted isoform can be gener-
ated either by alternative splicing (Ob-Re) or by ectodomain
shedding, and may be involved in modulating leptin activity
[17].
2. Structure and evolutionary relationships of the LR
extracellular domain
The LR was ¢rst cloned from a mouse choroid plexus
cDNA library using an expression cloning strategy by Tarta-
glia and co-workers [7]. Based on sequence homology, this
receptor belongs to the class I cytokine receptor family, which
typically contains a so-called CRH (cytokine receptor homol-
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ogy) domain in its extracellular domain. This structure con-
sists of two barrel-like domains, each approximately 100 ami-
no acids in length, which resemble the ¢bronectin type III
(FN III) fold. Two conserved disul¢de bridges are found in
the N-terminal domain, while a WSXWS motif is character-
istic for the C-terminal part. The LR shares highest sequence
similarity with the granulocyte colony-stimulating factor (G-
CSF) receptor and the glycoprotein 130 (gp130) family recep-
tors, including gp130, the leukemia inhibitory factor (LIF)
and oncostatin M (OSM) receptors. Moreover, structural
superposition shows that also leptin is structurally most sim-
ilar to G-CSF and cytokines of the gp130 family, such as
interleukin-6 (IL-6).
Fig. 1A shows a consensus phylogenetic tree, based upon
multiple sequence alignment of the membrane-proximal
CRHs. The tree shown in Fig. 1 was calculated using the
neighbor-joining distance method [18] with the Seqboot,
Protdist and Neighbor programs of the PHYLIP package
[19]. In this tree, the LR is most closely related to the OSM
and LIF receptors, although the bootstrap support value for
this evolutionary relationship is very low (40%). A parsimony
tree, calculated using PAUP [20], shows an identical image,
and supports the close evolutionary relationship between the
LR and the LIF and OSM receptors (bootstrap support value
39%). A parsimony tree, calculated using the Seqboot and
Protpars programs of the PHYLIP package [19] however,
suggests that the LR would be more closely related to the
G-CSF receptor and gp130 (bootstrap support value = 25%).
This relationship is also clearly re£ected in the overall ar-
chitecture of the ectodomains of these receptors (Fig. 1B):
besides a canonical CRH domain, the receptors for leptin,
G-CSF, LIF, OSM and gp130 all contain an immunoglobu-
lin-like (Ig-like) domain (Fig. 1B). The LR and LIF receptors
have an additional N-terminal CRH module, the OSM recep-
tor has a truncated N-terminal CRH module. While gp130
and the G-CSF, LIF and OSM receptors each contain three
membrane-proximal FN III domains, the LR stands out, hav-
ing only two.
Fig. 1. A: Protdist phylogenetic tree of leptin and other long-chain cytokine receptors, based on an alignment of the membrane-proximal
CRH. Numbers under the branches indicate the percent bootstrap support values out of 1000 bootstraps. PRLR: prolactin receptor; GHR:
growth hormone receptor; EpoR: erythropoietin receptor; OSMR: oncostatin M receptor; LIFR: leukemia inhibitory factor receptor;
G-CSFR: granulocyte colony-stimulating factor receptor; CNTFRK : ciliary neurotrophic factor receptor; IL-6RK : interleukin 6K receptor;
IL-11RK : interleukin 11K receptor. B: Schematic presentation of the overall structure of long-chain cytokine receptors. The di¡erent domains
are represented by colored squares or ovals, as explained below the ¢gure.
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3. Models for leptin/LR complex formation
Fong and co-workers generated a panel of LR deletion and
substitution mutants, and showed that the membrane-proxi-
mal CRH domain is necessary and su⁄cient for leptin bind-
ing. These authors further provide evidence that the two FN
III domains have no a⁄nity for the ligand, but nevertheless
are essential for receptor activation [21]. Recently, we could
de¢ne a critical role for the Ig-like domain in receptor activa-
tion. Receptors lacking this domain are properly expressed on
the cell surface, and bind leptin comparable to the wild type
receptor, but are unable to activate the associated Janus ki-
nases (JAKs) and fail to generate a signal transducer and
activator of transcription (STAT)-3-dependent signal (see be-
low; Zabeau et al., submitted).
Like all other class I cytokines, leptin adopts a four helical
bundle structure. These cytokines usually interact with their
receptor with two binding sites located on the helical faces of
helices D (site I) and A and C (site II). A unique feature of G-
CSF and of the gp130 family of cytokines is the presence of
an additional binding site III, at the N-terminus of helix D, in
one tip of the four helix bundle [22]. The function of this
binding site III and of the Ig-like domain in the gp130 recep-
tor systems was recently clari¢ed by the crystal structure of
the membrane-proximal CRH and Ig domain of gp130 in a
2:2 complex with Kaposi sarcoma herpesvirus IL-6 (vIL-6)
[23]. This complex contains two copies of the gp130 fragment
and of vIL-6. Each vIL-6 molecule interacts with two gp130
molecules by two interactions: binding site II in vIL-6 inter-
acts with the CRH of one gp130 molecule, while binding site
III in vIL-6 interacts with the Ig-like domain of a second
gp130 molecule. This 2:2 tetrameric type of complex forma-
tion is very likely also a good model for the G-CSF:G-CSFR
complex (Fig. 2A) [24]. Human IL-6 binds to its receptor in a
2:2:2 hexameric complex consisting of IL-6, IL-6RK and
gp130. In a generally accepted model, two human IL-6 mol-
ecules ¢rst bind to the CRH domains of dimeric IL-6RK with
their binding site I, and then bind to two gp130 receptor
molecules with binding sites II and III [23,25] (Fig. 2B). It
is tempting to speculate that similar clustering mechanisms
also take place in the leptin/LR complex (Fig. 2C,D).
In gp130, the G-CSF receptor and the LIF receptor, the Ig-
like domain interacts with binding site III of their cognate
cytokine ligands. It is therefore very likely that a similar bind-
ing site III in leptin will interact with the Ig-like domain of the
LR, which would help explain the deleterious e¡ect of remov-
al of this domain in the LR (Zabeau et al., submitted). Com-
parison with the IL-6 and G-CSF receptor systems suggests
that leptin will bind its receptor either by its site I in the
helical face of helix D, or by its site II in the helical faces
of helices A and C. One of these sites probably interacts with
the membrane-proximal CRH, as this constitutes the major
leptin binding site [21]. Interactions between a binding site II
in leptin and the membrane-proximal CRH were also sug-
gested by molecular modeling of the leptin/LR complex
[26,27].
Like the OSM and LIF receptors, LR contains an addi-
tional N-terminal CRH. In the LIF receptor, deletion of
this CRH leads to a constitutively active receptor [28]. This
is reminiscent of the constitutive activation seen in the fatty
Zucker rat LR, which carries a mutation in this domain [29].
In the LIF receptor, this N-terminal CRH is able to interact
with the ciliary neurotrophic factor receptor [30], suggesting a
possible role for receptor/receptor interaction for the N-termi-
nal CRH in the LR.
The membrane-proximal FN III domains of gp130 and of
the LIF receptor interact with each other [31]. Although De-
vos et al. [32] showed that the membrane-proximal FN III
domains are not necessary for dimerization of a soluble re-
combinant extracellular LR domain, similar interactions in
the membrane-anchored LR cannot be excluded.
An important, unresolved question in LR biology is how
LRlo can signal in the presence of excess LRsh. In many cell
types, mRNA for the latter may account for up to 95% of all
LR transcripts [33]. One possible explanation for this relative
signaling insensitivity of LRlo to the e¡ect of co-expression of
dominant negative LR isoforms may be the formation of
higher order clusters [29]. Based on the behavior of signal-
Fig. 2. Schematic representation of the complexes between cytokines and the extracellular domains of their receptors. A: G-CSF/G-CSF recep-
tor 2:2 complex. B: IL-6/gp130/IL-6K receptor 2:2:2 complex. C: Model for a 2:2 leptin/LR complex. D: Model for a 2:4 leptin/LR complex.
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ing-de¢cient LR mutants, we recently provided additional bio-
chemical data to support this hypothesis (Zabeau et al., sub-
mitted). Like all other class I cytokine receptors, the LR lacks
any intrinsic kinase activity, and uses cytoplasmic-associated
kinases of the JAK family. Leptin binding results in formation
of a receptor complex leading to cross-phosphorylation and
activation of the JAKs. These activated JAKs then rapidly
phosphorylate tyrosine residues in the cytosolic domain of
the receptor. Such phosphorylated residues provide binding
sites for signaling molecules including members of the STAT
family. STATs themselves are also subject to JAK-mediated
phosphorylation, inducing their homo- or heterodimerization,
their release from the receptor complex, and subsequent trans-
location to the nucleus, where they can modulate transcription
of speci¢c target genes (for more details, see below). Two LR
mutants, one de¢cient in the activation of JAK kinases (LR
vbox 1), the other unable to recruit STAT3 molecules (LR-
F3), are only able to signal when they are co-expressed. Based
on the requirements for JAK/STAT signaling, and on the lack
of signaling complementation with similar receptor constructs,
but containing the extracellular domain of the homodimeric
erythropoietin receptor, this observation implies that more
than two receptors must be clustered by leptin. When LRlo
and LRsh forms are co-expressed, such higher order clustering
can be expected to generate relatively more signaling-compe-
tent receptor complexes, when compared to simple homodi-
meric clustering. It is of note that the additional N-terminal
CRH (or even the FN III domains) may contribute to even
more complex patterns of receptor clustering.
An alternative explanation was suggested by White and co-
workers [34]. These authors showed ligand-independent
homo-oligomerization of LRlo and LRsh. Hetero-oligomeri-
zation between the two isoforms was only observed in the
presence of ligand. Therefore, di¡erential sorting, perhaps
based on the ability to bind JAKs, of LRsh and LRlo may
permit e⁄cient leptin signaling by the latter form. Di¡erential
sorting of the two isoforms is also suggested by the observa-
tion that LRsh could be involved in active transcytosis of
leptin [16].
4. Activation of the JAK/STAT signaling pathway
A general overview of cellular events following LR activa-
tion is shown in Fig. 3. Leptin signaling occurs typically
through the JAK/STAT pathway (see above). After ligand-
induced clustering, the LRlo predominantly activates JAK2
[35], although JAK1 activation has also been demonstrated
in some settings [36]. JAKs associate constitutively with a
conserved box 1 motif, which is characterized by two essen-
tially invariant prolines, in the class I cytokine receptors.
Some receptors also contain an additional sequence, box 2,
which is required for (maximal) JAK activation. In the murine
LRlo, a box 1 motif (intracellular amino acids 6^17) critical
for JAK2 activation and a putative box 2 motif (intracellular
amino acids 49^60) have been identi¢ed. The latter may be
required for maximal activation [35,37].
The LRlo has three conserved tyrosines in its cytoplasmic
domain, which correspond in the murine receptor to positions
Y985, Y1077 and Y1138. Y1138 is situated in a typical
STAT3 recruitment or YxxQ motif, similar to motifs found
in the gp130 family of receptors. After phosphorylation of this
site, STAT3 is recruited via its SH2 (Src homology) domain.
Activation, homo-dimerization and nuclear translocation of
STAT3 will then lead to speci¢c gene induction. The critical
role of this site is underscored by the dramatic obese pheno-
type observed in knock-in mice containing a Y1138S mutation
in LRlo [38]. It is unclear whether STAT3 is the only STAT
factor that is activated upon stimulation. Vaisse and col-
leagues could demonstrate the activation of STAT3, but not
of other STAT factors in the hypothalamus of leptin-treated
ob mice [39]. In cell lines however, STAT1 and STAT5B acti-
vation was also shown [40]. The fact that LRlo Y1138S
knock-in mice clearly have defects in body weight regulation
but not in fertility, as opposed to mice lacking functional LRs,
suggests alternative pathways, possibly via other STAT fac-
tors [38].
5. Role of phosphatases and of SOCS proteins
Mutation of the Y985 site in the receptor leads to enhanced
signaling after leptin stimulation [36,41,42]. The Y985 site was
identi¢ed as a recruitment site for the receptor-associated
SH2-containing phosphatase-2 (SHP-2) [36,41]. It remains un-
clear whether negative e¡ects are exerted via the phosphatase
activity of SHP-2, or via the suppressor of cytokine signaling
(SOCS)-3 protein, as it was later shown that this strong in-
hibitor of cytokine signaling also binds to the Y985 site
[43,44]. SHP-2-dependent dephosphorylation of JAK2, how-
Fig. 3. LR signaling. The LR carries three conserved tyrosines in its
cytoplasmic domain. JAK2, which associates membrane-proximally
with the receptor, becomes activated upon ligand binding and phos-
phorylates these tyrosine residues. The membrane-distal Y1138 func-
tions as a docking site for STAT3 which itself is a substrate of
JAK2. Upon subsequent dimerization, it translocates to the nucleus
and induces expression of SOCS3 and other genes. The membrane-
proximal Y985 and Y1077 are involved in regulation and attenua-
tion of the leptin signal. SOCS3 is taking part in a feedback loop
inhibiting leptin signaling by binding to both tyrosines although
binding a⁄nity for Y1077 is much weaker. SHP2 is recruited to the
Y985 position and activates the MAPK pathway through the adapt-
er protein Grb-2, ultimately inducing c-fos expression. PTP1B is lo-
calized on the surface of the endoplasmic reticulum, and is also
involved in negative regulation of LR signaling through dephos-
phorylation of JAK2 after internalization of the LRlo complex.
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ever, also suggests an inhibiting function for SHP-2 in regu-
lation of LRlo signaling [45]. SOCS proteins act in a typical
negative feedback loop: they are rapidly induced after cyto-
kine stimulation, and directly inhibit the receptor via various
mechanisms, including receptor targeting to the proteasome.
Both SOCS1 and SOCS3 can inhibit leptin signaling, and the
observation that SOCS3 expression levels are elevated in the
lethal yellow (Ay/a) obese mouse strain makes it a potential
mediator of leptin resistance in vivo [46]. SOCS3 gene tran-
scription is very rapidly induced in vitro and in vivo after
leptin treatment [46,47], and even serves as a marker to map
leptin-responsive neurons in the hypothalamus [48].
The function of the highly conserved Y1077 site is still
unclear, mainly because phosphorylation of this site remains
to be demonstrated. Remarkably, the Y985 and Y1077 sites
are highly similar, suggesting binding of common signaling
molecules. The Y1077 site shows weak interaction with
SOCS3 and can therefore have an additive e¡ect in signal
termination [44].
SHP-2 is proposed as a positive regulator of leptin signaling
through mitogen-activated protein kinase (MAPK) activation.
Docking to Y985 is followed by recruitment of the adapter
protein growth receptor bound 2 (Grb-2) and activation of the
Ras/Raf pathway. A secondary pathway for leptin-induced
MAPK signaling, directly via JAK2, probably requires the
phosphatase activity of SHP-2. The MAPK pathway is re-
sponsible for leptin-induced c-fos activation [49]. It is of
note that in LRlo signal transduction SOCS3 may also func-
tion as an adapter protein to other pathways [50].
Mice lacking PTP1B (phosphotyrosine phosphatase 1B) are
hypersensitive to insulin and leptin and exhibit resistance to
high fat diet obesity [51]. PTP1B recognizes a speci¢c consen-
sus substrate motif, (E/D)-pY-pY-(R/K), which was identi¢ed
in JAK2 and the kinase activation loop of the insulin receptor
[52,53]. Over-expression of PTP1B resulted in hypophosphor-
ylation of endogenous JAK2 and blocked the leptin-induced
transcription of endogenous SOCS3 and c-fos in a hypotha-
lamic cell line. PTP1B appears to be a negative mediator of
both the JAK/STAT and MAPK pathways in LR signaling
and may be implicated in leptin resistance [54]. PTP1B is
localized exclusively on the endoplasmic reticulum [55]. How
PTP1B interacts with its substrates is not yet clear, although
prior internalization of the receptor complex is suggested, es-
pecially since JAK2 has been detected at the endoplasmic
reticulum [56].
6. Role of PI3 kinase
A strong correlation is assumed between the leptin and
insulin signaling pathways since leptin and insulin resistance
occur coincidentally in the majority of obese humans. Cross-
talk between these pathways can be readily observed in vari-
ous cell lines and in vivo. Phosphorylation of the insulin re-
ceptor substrates 1 and 2 (IRS1 and 2) as well as their inter-
action with Grb-2 and phosphatidylinositol 3-kinase (PI3K)
show clear modulation by leptin in various hepatocytic cell
lines [13,57]. Kim and colleagues performed a detailed in vivo
study in rats showing STAT3 activation in insulin-responsive
tissues after intraperitoneal injection of leptin. They also ob-
served modulation of the PI3K and Grb-2 interaction with
both IRS1 and IRS2 [58]. The apparent discrepancies de-
scribed by various authors suggest that leptin and insulin
signaling pathways interact in di¡erent ways depending on
tissue type and cell line.
PI3K is also activated via IRS2 in the hypothalamus of
rats, and appears to be crucial for the weight-reducing proper-
ties of leptin. Impaired PI3K signaling in peripheral tissues of
obese individuals may also contribute to obesity-induced in-
sulin resistance. A similar mechanism may explain the desen-
sitization of leptin signaling in the hypothalamus, ultimately
resulting in leptin resistance and obesity [59].
7. Concluding remarks
It is generally accepted that leptin plays a central role in
regulating body weight. However, treatment of obesity using
recombinant leptin seems to be only e¡ective in individuals
with a rare homozygous mutation in the gene for leptin or its
receptor, or who exhibit subnormal secretion of the hormone,
ruling out its current use as a generic drug. In most cases,
obese humans have elevated leptin levels, indicative of leptin
resistance. Unraveling the molecular mechanisms underlying
this leptin resistance is therefore of great clinical interest. Giv-
en the complexity of the physiological processes controlling
body weight, many defects may underlie leptin resistance. One
possibility is a defect in the passage of leptin through the
blood^brain barrier. It was suggested that the LR short iso-
form plays a role in this transport, but the precise mechanism
is still a matter of debate and some evidence points to a
hitherto uncharacterized leptin transporter in the brain capil-
lary endothelium. Also, leptin resistance might result from a
defect at the level of LR activation in the hypothalamic nuclei
causing inappropriate sensing of the leptin levels. A better
understanding of LR activation may help in understanding
this, and may also provide a molecular explanation for the
relative insensitivity of LR signaling in the presence of excess
dominant negative LRsh receptors. Defects in LR signal
transduction could be important as well, and in this light,
negative regulators of signaling like SOCS3 and PTP1B are
of special interest and may represent targets for the treatment
of human obesity.
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